Autologous Hematopoietic Stem Cell Gene Therapy Market Global Report 2026

The autologous hematopoietic stem cell gene therapy market size has grown exponentially in recent years. It will grow from $5.23 billion in 2025 to $6.3 billion in 2026 at a compound annual growth rate (CAGR) of 20.6%. The growth in the historic period can be attributed to advancements in viral vector technologies, increasing prevalence of rare genetic disorders, growth in stem cell transplantation procedures, rising clinical success of ex vivo therapies, expansion of regenerative medicine research.

The autologous hematopoietic stem cell gene therapy market size is expected to see exponentially grown in the next few years. It will grow to $13.44 billion in 2030 at a compound annual growth rate (CAGR) of 20.8%. The growth in the forecast period can be attributed to expanding commercialization of gene editing therapies, increasing regulatory approvals for advanced therapies, growth in personalized medicine adoption, rising investment in cell and gene therapy infrastructure, development of next generation non viral delivery platforms. Major trends in the forecast period include autologous stem cell engineering platform advancement, expansion of ex vivo hematopoietic stem cell modification therapies, increasing adoption of personalized curative treatments for rare genetic disorders, development of next generation viral and non viral gene delivery systems, growing clinical pipeline for hematopoietic stem cell based regenerative therapies.

The increasing healthcare investment in rare diseases is expected to propel the growth of the autologous hematopoietic stem cell gene therapy market going forward. Rare diseases refer to disorders that affect fewer than 1 in 2,000 people, often involving complex symptoms and limited treatment options. Healthcare investment in rare diseases is increasing due to growing government incentives, including orphan drug policies, tax credits, and regulatory support, which encourage pharmaceutical companies to invest in the development of treatments for small and underserved patient populations. Increasing healthcare investment in rare diseases is accelerating the development and adoption of autologous hematopoietic stem cell gene therapy by funding advanced research, supporting clinical trials, and improving access to high-cost personalized treatments that address the underlying genetic causes of rare blood and immune disorders. For instance, in April 2024, according to Global Genes, a US-based nonprofit organization, in the first quarter of 2024, companies developing drugs for rare diseases raised $7.1 billion through public equity and debt financings, representing a 307% increase compared to the $1.8 billion raised during the same period in 2023. Therefore, the increasing healthcare investment in rare diseases is driving the growth of the autologous hematopoietic stem cell gene therapy market.

Key companies operating in the autologous hematopoietic stem cell gene therapy market are focusing on developing innovative therapies, such as CRISPR/Cas9-based gene-edited treatments, to address rare genetic blood disorders and improve long-term disease modification. CRISPR/Cas9-based gene-edited treatments are advanced therapies that use the CRISPR gene-editing system and Cas9 enzyme to precisely modify faulty DNA in a patient’s cells, helping by correcting the genetic cause of disease so the body can produce healthy cells or proteins, potentially reducing symptoms long-term or providing a one-time curative treatment instead of ongoing therapy. For example, in February 2024, Vertex Pharmaceuticals Inc., a US-based biotechnology company, received conditional marketing authorization from the European Commission for CASGEVY (exagamglogene autotemcel), a CRISPR/Cas9 gene-edited therapy developed in collaboration with CRISPR Therapeutics, for the treatment of patients aged 12 years and older with severe sickle cell disease and transfusion-dependent beta thalassemia. The therapy is designed to edit hematopoietic stem cells outside the body and reinfuse them to enable sustained production of functional hemoglobin, thereby reducing or eliminating vaso-occlusive crises and the need for regular blood transfusions.

In October 2025, AGC Biologics Inc., a US-based contract development and manufacturing organization (CDMO), partnered with Rarity Public Benefit Corporation to support the development and Good Manufacturing Practice (GMP) manufacturing of its gene therapy program RDP-101 for Adenosine Deaminase Severe Combined Immunodeficiency Disorder. Through this partnership, AGC Biologics Inc. will provide comprehensive development and GMP manufacturing services to help advance Rarity Public Benefit Corporation’s gene therapy program toward clinical use, leveraging its expertise in integrated cell and gene therapy production to support treatment development for rare genetic conditions. Rarity Public Benefit Corporation (Rarity PBC) is a US-based biotechnology research company specializing in ex vivo autologous hematopoietic stem cell (HSC) gene therapy, including its RDP-101 program.

Major companies operating in the autologous hematopoietic stem cell gene therapy market are Novartis AG; Vertex Pharmaceuticals Incorporated; CSL Behring LLC; Orchard Therapeutics; Genetix Biotherapeutics; Crispr Therapeutics AG; Rocket Pharmaceuticals; Editas Medicine Inc.; Sangamo Therapeutics Inc.; Beam Therapeutics Inc.; Prime Medicine Inc.

North America was the largest region in the autologous hematopoietic stem cell gene therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the autologous hematopoietic stem cell gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the autologous hematopoietic stem cell gene therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The autologous hematopoietic stem cell gene therapy market consists of revenues earned by entities by providing services such as stem cell collection, genetic modification of hematopoietic stem cells, viral vector development, cell processing, gene-editing procedures, cryopreservation, and personalized regenerative therapy administration. The market value includes the value of related goods sold by the service provider or included within the service offering. The autologous hematopoietic stem cell gene therapy market also includes sales of stem cell transplantation kits, cell culture media, bioprocessing equipment, and therapeutic cell products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The autologous hematopoietic stem cell gene therapy market research report is one of a series of new reports that provides autologous hematopoietic stem cell gene therapy market statistics, including autologous hematopoietic stem cell gene therapy industry global market size, regional shares, competitors with a autologous hematopoietic stem cell gene therapy market share, detailed autologous hematopoietic stem cell gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the autologous hematopoietic stem cell gene therapy industry. This autologous hematopoietic stem cell gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.